Schedule 13D ownership disclosure

Spero Therapeutics Inc

Security class unavailable · CUSIP: 84833T103

Event date: 2021-02-12

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
10,311,601
Percent of class
3.8000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001839882-21-002172
Form type
SC 13D/A
Filer
Atlas Venture Fund X, L.P.
CIK
CIK 1628098
Filed
Feb 16, 2021
Reporting period
Feb 12, 2021
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub